Drug updated on 12/11/2024
| Dosage Form | Tablet (oral; 200 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- Maribavir has been approved for the treatment of post-transplant cytomegalovirus (CMV) infection or disease, specifically in adolescents, demonstrating its effectiveness in this population.
- Maribavir has shown effectiveness in managing refractory or resistant CMV infections in transplant recipients, making it a valuable option for patients whose infections do not respond to other treatments.
- No significant differences in effectiveness among different population types or subgroups for maribavir were reported in the reviewed studies.
- There is no specific safety information available for maribavir in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Livtencity (maribavir) Prescribing Information. | 2024 | Takeda Pharmaceuticals America Inc., Lexington, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation | 2024 | Viruses |
| Anti-CMV therapy, what next? A systematic review | 2023 | Frontiers in Microbiology |